Michael Skynner Joins Sortera Bio’s Board of Directors as Non-Executive Director, Bringing Extensive Expertise in Biotechnology and Pharmaceutical Industries
Cambridge, UK – 14 April 2025 – Sortera Bio Ltd, is pleased to announce the appointment of Michael Skynner to its Board of Directors.
Michael Skynner Ph.D., is currently the chief technology officer at Bicycle Therapeutics plc. and previously served as Bicycle’s chief operations officer. Michael joined Bicycle from Pfizer, where he led rare disease efforts in Europe and founded and ran the Pfizer Rare Disease Consortium (RDC) and established Pfizer’s Genetic Medicine Institute. Previously, Michael established a discovery unit at GlaxoSmithKline (GSK) focused on developing therapeutics targeting inflammatory kinases, where he successfully advanced multiple molecules from screening into clinical trials. Prior to GSK, he co-founded a successful biotech start-up company, Cambridge Biotechnology Ltd. (CBT), which was sold to Swedish Orphan Biovitrum. Michael obtained his Ph.D. in biochemistry at Imperial College and is an author on more than 30 peer-reviewed scientific publications.
Michael brings a wealth of experience in the discovery and development of novel therapeutics across multiple disease areas and modalities. He has successfully founded and grown a range of new business entities, evolving them into successful ventures through strong organisational leadership. His breadth of expertise in a range of diverse roles across the pharmaceutical and biotechnology sectors is highly sought after in early-stage biotechnology companies and this strategic addition strengthens the team.
“I welcome the addition of Michael to the board as he brings an enormous breadth of strategic, scientific and operational experience. His expertise will both strengthen Sortera’s board and be influential in guiding the company strategy. His drug discovery skills will help Sortera further develop its technology platform and apply it to address some of the greatest challenges in drug discovery. I look forward to working alongside Michael on this journey” said Ben Porebski, CEO/CTO Sortera Bio.
“I’m delighted to be joining the board of Sortera Bio to help the team further evolve its innovative and disruptive Deep Screening Technology and apply it to solve challenges in biologics drug discovery and bring forward the next generation of therapeutics” said Michael Skynner.
ENDS
About Sortera Bio
Sortera Bio Ltd is a Cambridge UK-based biotechnology company based on intellectual property developed at the MRC Laboratory of Molecular Biology. Sortera is focused on accelerating the discovery of biologics via its proprietary Deep Screening platform and is dedicated to delivering transformative solutions in biologics discovery to meet the needs of patients worldwide.
Contact: hello@sortera.bio
https://sortera.bio
Follow Sortera Bio on LinkedIn